Clinical Trial Update: TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors; the trial status was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• TLD-1 (liposomal doxorubicin)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Advanced Solid Tumors | Phase 1 | Status: TERMINATED